Format

Send to

Choose Destination
Pharmacogenomics J. 2015 Dec;15(6):505-12. doi: 10.1038/tpj.2015.8. Epub 2015 Mar 17.

Genetic variants in DNA repair genes as potential predictive markers for oxaliplatin chemotherapy in colorectal cancer.

Author information

1
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
2
Division of Preventive Oncology, National Center for Tumor Diseases (NCT) and DKFZ, Heidelberg, Germany.
3
Division of Clinical Epidemiology and Aging Research, DKFZ, Heidelberg, Germany.
4
Division of Biostatistics, DKFZ, Heidelberg, Germany.
5
Division of Molecular Epidemiology, DKFZ, Heidelberg, Germany.
6
Division Molecular Biology of Breast Cancer, Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany.
7
Division of Epigenomics and Cancer Risk Factors, DKFZ, Heidelberg, Germany.
8
Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, University of Heidelberg, Heidelberg, Germany.
9
Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
10
German Cancer Consortium (DKTK), Heidelberg, Germany.

Abstract

Oxaliplatin-based chemotherapy exerts its effects through generating DNA damage. Hence, genetic variants in DNA repair pathways could modulate treatment response. We used a prospective cohort of 623 colorectal cancer patients with stage II-IV disease treated with adjuvant/palliative chemotherapy to comprehensively investigate 1727 genetic variants in the DNA repair pathways as potential predictive markers for oxaliplatin treatment. Single nucleotide polymorphisms (SNP) associations with overall survival and recurrence-free survival were assessed using a Cox regression model. Pathway analysis was performed using the gamma method. Patients carrying variant alleles of rs3783819 (MNAT1) and rs1043953 (XPC) experienced a longer overall survival after treatment with oxaliplatin than patients who did not carry the variant allele, while the opposite association was found in patients who were not treated with oxaliplatin (false discovery rate-adjusted P-values for heterogeneity 0.0047 and 0.0237, respectively). The nucleotide excision repair (NER) pathway was found to be most likely associated with overall survival in patients who received oxaliplatin (P-value=0.002). Our data show that genetic variants in the NER pathway are potentially predictive of treatment response to oxaliplatin.

PMID:
25778469
PMCID:
PMC4573779
DOI:
10.1038/tpj.2015.8
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center